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Abstract
Background: Toxoplasma gondii can infect almost all warm-blood animals including human beings. The high
incidence and severe damage that can be caused by T. gondii infection clearly indicates the need for the
development of a vaccine. T. gondii elongation factor 1-alpha (TgEF-1α) plays an important role in pathogenesis and
host cell invasion for this parasite. The aim of this study was to evaluate the immune protective efficacy of a DNA
vaccine encoding TgEF-1α gene against acute T. gondii infection in mice.
Methods: A DNA vaccine (pVAX-EF-1α) encoding T. gondii EF-1a (TgEF-1α) gene was constructed and its immune
response and protective efficacy against lethal challenge in BALB/c mice were evaluated.
Results: Mice inoculated with the pVAX-EF-1α vaccine had a high level of specific anti-T. gondii antibodies and produced
high levels of IFN-gamma, interleukin (IL)-4, and IL-17. The expression levels of MHC-I and MHC-II molecules as well as the
percentages of both CD4+ and CD8+ T cells in mice vaccinated with pVAX-EF-1α were significantly increased (p < 0.05),
compared with those in all the mice from control groups (blank control, PBS, and pVAXI). Immunization with pVAX-EF-1α
significantly (p < 0.05) prolonged mouse survival time to 14.1 ± 1.7 days after challenge infection with the virulent T. gondii
RH strain, compared with mice in the control groups which died within 8 days.
Conclusions: DNA vaccination with pVAX-EF-1α triggered strong humoral and cellular responses and induced effective
protection in mice against acute T. gondii infection, indicating that TgEF-1α is a promising vaccine candidate against
acute toxoplasmosis.
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Background
Toxoplasma gondii, an obligate intracellular protozoan
parasite, is responsible for toxoplasmosis in a wide range
of hosts including humans, mammals, birds, shellfish and
marine mammals [1–5]. In immunocompetent individ-
uals, T. gondii infection is usually asymptomatic or solely
causes mild symptoms but can result in severe disease,
such as ocular toxoplasmosis or encephalitis in immuno-
compromised patients, and it causes congenital birth de-
fects [6, 7]. In addition to the risk to human health, T.
gondii infection of agriculturally important animals, such
as goats, sheep, and pigs, also causes significant economic
losses due to animal abortions and neonatal losses [5, 8].
Currently, chemotherapy is the primary strategy in the
treatment of the acute phase of this disease, but it is not
effective against T. gondii chronic infection [9]. Due to
the emergence of drug-resistant parasites and the chem-
ical residues in food that are associated with drug use
[10–12], there is an urgent need for an efficient vaccine
against toxoplasmosis. During the past decade, anti-T.
gondii live, attenuated-live, killed and subunit vaccines
have been developed [10]. Although the only licensed T.
gondii vaccine, which is based on the attenuated-live T.
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gondii S48 strain (Toxovax®), can be used to prevent the
incidence of abortion in sheep [13], further exploration
of its use in other food-producing animals or in humans
has been hampered by safety concerns on the possibility
of its reversion to a virulence wild type. A DNA vaccine
is therefore a better alternative because it does not re-
quire the preparation of a whole organism preparation
and it has the potential to induce both specific humoral
and cellular immune responses as well as long-lasting
immunity [10]. In recent years, DNA vaccines against T.
gondii have been developed and have received consider-
able attention as good vaccine options [14].
Elongation factor 1-alpha (EF-1α) is highly conserved
and ubiquitously expressed in all eukaryotic cells [15–17].
It plays a central role in protein synthesis within
eukaryotic cells, and is responsible for aminoacyl-tRNA
loading onto the A site of the ribosome [18]. Additionally,
it appears to have a number of other functions associated
with cell growth, motility, protein turnover, and signal
transduction [19]. Recent studies have also suggested that
this protein is involved in DNA replication/repair protein
networks [20] and apoptosis [21].
In parasites, EF-1α has been implicated in pathogen-
esis [22] and host cell invasion [23]. Cryptosporidium
parvum (C. parvum) EF-1α protein, which localizes at
the apical region of the parasite, mediates cryptospori-
dial cytoskeletal complex formation. An anti- EF-1α
mAb significantly inhibited the host cell invasion by C.
parvum in vitro. These results indicate that C. parvum
EF-1α plays an essential role in mediating host cell entry
by the parasite and, as such, could be a candidate vac-
cine antigen against cryptosporidiosis [23]. However, to
our knowledge, no studies have evaluated the immuno-
genicity of T. gondii EF-1α (TgEF-1α) and its potential
as a vaccine candidate against T. gondii infection.
The objective of the present study was to evaluate the
potential of TgEF-1α as a vaccine candidate against acute
T. gondii infection. Therefore, we assessed various im-
mune responses in BALB/c mice that received DNA




The experiments were conducted following the guide-
lines of the Animal Ethics Committee, Nanjing Agricul-
tural University, China. All experimental protocols were
approved by the Science and Technology Agency of
Jiangsu Province (approval ID, SYXK (SU) 2010–0005).
Mice and cell culture
Five-week-old female BALB/c mice were purchased from
the Center of Comparative Medicine, Yangzhou University
(Yangzhou, China) and maintained under specific-
pathogen-free conditions.
Baby hamster kidney (BHK) cells were grown and main-
tained in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco, Beijing, China) supplemented with L-glutamine,
10 % dialyzed fetal bovine serum (FBS; Gibco, USA),
100 IU/ml penicillin, and 100 μg/ml streptomycin in a hu-
midified chamber containing 5 % CO2 at 37 °C.
Parasites and preparation of soluble tachyzoite antigens
(STAg)
T. gondii RH strain (Type I) was provided by the La-
boratory of Veterinary Molecular and Immunological
Parasitology, Nanjing Agricultural University, China.
The parasites were maintained and collected from the
peritoneal cavity of infected BALB/c mice as described
previously [24].
Purified tachyzoites were disrupted by three cycles of
freezing at −20 °C and thawing at 4 °C. After that, the ly-
sates were sonicated on ice at 60 W/s and centrifuged
for 30 min at 12,000 × g. The supernatants were pooled
and sterile filtered, and the protein concentration was
determined via the Bradford method using bovine serum
albumin (BSA) as the standard. STAg was stored in ali-
quots at −70 °C until use.
Construction of the DNA vaccine plasmid
The complete open reading frame (ORF) of TgEF-1α
(GenBank accession no. XM_002370208.1) was ampli-
fied by reverse transcription-polymerase chain reaction
(RT-PCR) using designed specific primers (forward pri-
mer: 5′- CGCGGATCCATGGGTAAGGAAAAGACT
CACATTAAC −3′ and reverse primer: 5′- CCGCTCG
AGCGAAGCGGTAGATTTGTTCCAAT −3′), in which
the BamHI and XhoI restriction sites, respectively, were
introduced and are shown in italics here. Following
ligation of the obtained RT-PCR product with the
pMD19-T vector (Takara, Dalian, China) to form pMD-
EF-1a, the TgEF-1α fragment was cleaved from pMD-
EF-1a by BamHI and XhoI and subcloned into the
corresponding sites of pVAXI vector (Invitrogen,
Carlsbad, CA, USA). The resulting plasmid was
named pVAX-EF-1α. The concentration of the ex-
tracted pVAX-EF-1α was determined by spectropho-
tometry at OD260 and OD280.
Sequence analysis
The sequence similarity of TgEF-1α to EF-1α from other
species was studied using BLASTP and BLASTX (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). EF-1α sequences were
aligned using MEGA4.0.
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Expression of recombinant plasmids in vitro
Before transfection, BHK cells were transferred to 6-well
plates (Corning Costar, Cambridge, MA, USA). When
the confluency of the cells reached 80 %–90 %, 5 μg of
the recombinant eukaryotic plasmid (pVAX-EF-1α) was
used to transfect the cells using Lipofectamine 3000 re-
gent (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. The empty vector pVAXI
(5 μg) was also transfected into BHK cells as a negative
control. Lipofectamine 3000 reagent was respectively
mixed with pVAX-EF-1α or pVAXI at a concentration of
10 μg/ml in DMEM without Fetal Bovine Serum (FBS)
and antibiotics, and was incubated at room temperature
for 30 min. The mixture of lipofectamine and plasmid
was then added into BHK cells. The cells were incubated
with the transfection mixture for 6 h at 37 °C in the
presence of 5 % CO2. At the end of this incubation, fresh
growing medium was supplemented and plates were
returned to the cell incubator for further incubation.
After 48 h of incubation, the transfected cells were
treated on ice with RIPA lysis buffer (50 mM Tris
pH 7.4, 150 mM NaCl, 1 % Triton X-100, 1 % Sodium
deoxycholate and 0.1 % SDS) containing 1 mM protease
inhibitor phenylmethanesulfonyl fluoride (PMSF) and
centrifuged at 13,000 × g for 10 min. The translation of
the transfected genes in BHK cells was detected by west-
ern blot analysis with anti-T. gondii polyclonal antibody
(from chicken) as a primary antibody and a horseradish
peroxidase (HRP)-labeled goat anti-chicken IgG anti-
body (SouthernBiotech, Birmingham, AL, USA) as a sec-
ondary antibody. Finally, the membrane was soaked in
DAB Reagents (Boshide Biotech Co, Wuhan, China) for
signal development.
BALB/c mice immunization and challenge
To assess the immunogenicity of the recombinant plas-
mids, BALB/c mice were randomly divided into four
groups of 30 mice per group. Before vaccination, plas-
mids were diluted and suspended in sterile phosphate
buffered saline (PBS) to a final concentration of 1 μg/μl.
All experimental groups were injected intramuscularly
(i.m.) three times at weeks 0, 2, and 4 with plasmid
DNA (100 μg/each), PBS (100 μl/each) or empty plasmid
(100 μg/each), respectively, and one group of mice was
not inoculated, which served as a blank control. Blood
samples of mice were collected from the tail vein plexus
on the day before each vaccination and 2 weeks after the
last vaccination. The sera were obtained from the blood
samples and stored at −20 °C for evaluation of antibody
content and cytokine measurement. At weeks 0, 2, 4,
and 6, five mice from each group were sacrificed, and
the spleens were collected and used to isolate the splenic
lymphocytes for flow cytometry analyses. The remaining
ten mice in each group were used for the challenge
Fig. 1 Identification of the recombinant plasmid with restriction
enzyme digestion. Lanes 1, the eukaryotic construct pVAX-EF-1α was
double digested by BamH I and Xho I enzymes and the product was
resolved by 1 % agarose gel to verify a band of size 1347 bp. (M)
Represents DNA Molecular marker
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experiment. Two weeks after the last injection, mice
from all four groups were challenged intraperitoneally
(i.p) with 1 × 104 tachyzoites of T. gondii RH strain. The
survival times of the mice were observed and recorded
on a daily basis.
Determination of antibodies by ELISA
The levels of antibodies in mouse sera were determined
by enzyme-linked immunosorbent assay (ELISA) as pre-
viously described [25]. In brief, the microtiter plates
(Corning Costar, Cambridge, MA, USA) were coated
overnight at 4 °C with 10 μg /ml STAg in 50 mM car-
bonate buffer pH 9.6 (100 μl per well). After three
washes, the plates were blocked with 3 % Bovine Serum
Albumin (BSA) for 2 h at 37 °C and subsequently incu-
bated with the mouse sera diluted 1:10 in PBS for 1 h at
37 °C. HRP-conjugated goat anti-mouse IgA, IgM, IgE,
IgG, IgG1, or IgG2a (SouthernBiotech, Birmingham, AL,
USA) was used as the secondary antibody to detect
bound antibodies. Finally, the immune complexes were
developed by incubation with 3,3,5,5-tetramethylbenzi-
dine (TMB) for 20 min. The reaction was stopped by
adding 2 M H2SO4, and the absorbance was measured at
450 nm with an automated ELISA reader (Multiskan FC,
Thermo scientific, Waltham, MA, USA). All samples
were run in triplicate.
Cytokine assays
To assay cytokine production levels, sera from each ex-
perimental group were obtained as described above. Inter-
feron gamma (IFN-γ), interleukin-4 (IL-4), interleukin-17
(IL-17) and transformation growth factor-β1 (TGF-β1)
were measured using ELISA kits according to the manu-
facturer’s instructions (Boster Systems, Wuhan, China).
Cytokine concentrations were determined by reference to
standard curves constructed with known amounts of
mouse recombinant IL-4, IL-17, IFN-γ or TGF-β1. The
analysis was performed with the data from three inde-
pendent experiments.
Flow cytometry analysis of T cell subsets and MHC
molecules
The levels of CD4+ and CD8+ T cell subsets and the
levels of MHC-I and MHC-II molecules in the spleno-
cytes of mice from the four test groups, pVAX-EF-1α,
pVAXI, PBS, and blank, were determined using flow cy-
tometry as previously described [26]. Splenocyte suspen-
sions (1 × 106 cells/ml) were dually stained with anti-
mouse CD3e-FITC + anti-mouse CD8-PE, anti-mouse
CD3e-FITC + anti-mouse CD4-PE, anti-mouse CD3e-
FITC + anti-mouse MHC-I-PE or anti-mouse CD3e-
FITC + anti-mouse MHC-II-PE (eBioscience, San Diego,
CA, USA) for 30 min at 4 °C in the dark. Cell population
analyses were conducted with a FACScan flow cytometer
with CellQuest software (BD Biosciences, Franklin
Lakes, NJ, USA). Lymphocyte specific gating was set ac-
cording to the forward and side scatter profiles. The per-
centages of CD4+ and CD8+ T lymphocytes or, MHC-I
and MHC-II molecules in mouse splenocytes were de-
termined as previously described [27].
Statistical analysis
All statistical analyses were performed by IBM SPSS
20.0 Data Editor (SPSS Inc., Chicago, IL, USA). The dif-
ferences of the data (e.g., antibody responses and, cyto-
kine production) between all groups were compared by
one-way ANOVA. Survival times of the mice were com-
pared using the Kaplan–Meier method. The differences
between groups were considered statistically significant
if the p value was less than 0.05.
Fig. 2 The phylogenetic tree of amino acid sequences between TgEF-1α and those of EF-1α from other species
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Results
Successful construction of the eukaryotic expression
plasmids
The DNA vaccine pVAX-EF-1α was constructed as de-
scribed in the Methods. To test that the construction
was successful, an enzyme digestion was performed with
BamH I and Xho I, yielding a fragment of the expected
size, 1,347 pb (Fig. 1). A sequence analysis was also per-
formed and its results showed that the insert in the vec-
tor was the ORF of TgEF-1α. Together, these results
indicate that the DNA vaccine pVAX-EF-1α was con-
structed correctly.
TgEF-1α multiple sequence alignment and cladogram
When compared with the known EF-1α protein sequences
on the NCBI database (http://blast.ncbi.nlm.nih.gov/Blast.
cgi), the TgEF-1α amino acid sequence had 74 % identity
to Bos taurus (gi|14422440), Gallus gallus (gi|488468),
and Homo sapiens (gi|15421129), 73 % identity to Mus
musculus (gi|50797) and Sus scrofa (gi|350588388), 70 %
to Capra hircus (gi|548523658), and 67 % identity to
Canis lupus familiaris (gi|545523055).
In contrast, the TgEF-1α sequence had 99 % identity
to the EF-1α of T. gondii ME49 and T. gondii GT1, 98 %
identity to Neospora caninum (gi|401395932), 86 %
identity to Cryptosporidium hominis (gi|67601420), 85 %
identity to Eimeria acervulina (gi|557118408), and 83 %
identity to Babesia bovis (gi|156087152).
The phylogenetic tree of amino acid sequences was
built using MEGA4.0, and the resulting cladogram
(Fig. 2) showed that the kinship of TgEF-1α protein with
other species of apicomplexan parasites (Neospora cani-
num, Babesia bovis, Cryptosporidium hominis, and
Eimeria acervulina) was high when compared with its
kinship with other host species (Mus musculus, Bos
taurus, Gallus gallus, Canis lupus familiaris, Capra hir-
cus, Sus scrofa, and Homo sapiens).
Western blot analyses of proteins synthesized in vitro
BHK cells were transfected with pVAX-EF-1α. The ly-
sates of transfected cells were analyzed on immunoblots
(Fig. 3). The lysate of BHK cells transfected with pVAX-
EF-1α was specifically recognized by serum obtained
from a T. gondii infected chicken. In contrast, cells
transfected with pVAX I were not recognized by this
serum.
Humoral response induced by DNA immunization
To evaluate the level of antibody induced by three con-
secutive DNA immunizations, we collected serum sam-
ples prior to each vaccination as well as at 2 weeks after
the last immunization. Then, we performed ELISAs to
determine the total IgG, the distribution of IgG1 and
IgG2a isotypes, and the IgA, IgM, and IgE two weeks
after the last immunization. Compared with the three
control groups, a significantly higher level of IgG anti-
body was detected in the sera of mice immunized with
pVAX-EF-1α (p < 0.01), and the OD values of IgG con-
tinuously increased with successive DNA immuniza-
tions. There were no statistically significantly differences
in the IgG levels among the three control groups
(Fig. 4a).
The levels of IgG1 and IgG2a in the pVAX-EF-1α group
were also the highest in comparison with those in the
three control groups (p < 0.01) (Fig. 4b & c). An
Fig. 3 Identification of TgEF-1α in BHK cells by western blot analysis.
Lane 1, lysates of BHK cells transfected with pVAX-EF-1α was probed
with chicken anti-T. gondii sera. Lane 2, Lysates of BHK cells transfected
with empty pVAXI vector probed with chicken anti-T. gondii sera. (M)
Pre-stained protein molecular marker
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apparent predominance of IgG2a over IgG1 was ob-
served in immunized mice, demonstrating that a Th1-
type cell immune response was elicited by immunization
with pVAX- EF-1α.
Regarding the IgA, IgM, and IgE levels, in comparison
with the levels in the control groups, the dynamics of
IgA and IgM demonstrated significantly higher OD
values (p < 0.01) in the immunized group: 0.533 ± 0.037
and 0.701 ± 0.048, respectively (Fig. 4d & e). However,
IgE activity showed no significant differences between
any of the groups at the time of evaluation (Fig. 4f ).
Cytokine production
Sera samples collected at weeks 0, 2, 4, and 6 were used
to measure the amounts of IFN-γ, IL-4, IL-17, and TGF-
β1 produced in the different experimental groups. As
shown in Fig. 5a, significantly higher levels of IFN-γ
were observed in mice immunized with pVAX-EF-1α
compared to the three control groups at 2, 4, and
6 weeks post-immunization. Small amounts of IL-4 and
IL-17 were also secreted by mice in the pVAX-EF-1α
group post-immunization, which although modest, were
still significantly higher than the amounts secreted by
mice in any of the three control groups post-
immunization (p < 0.05) (Fig. 5b & c). In contrast, the
levels of TGF-β1 displayed no significant changes be-
tween any of the groups at similar times of evaluation
(Fig. 5d).
T lymphocytes CD4+ and CD8+subpopulations and MHC
molecule changes
As illustrated in Table 1 and Fig. 6a, the percentage of
CD4+ T cells was significantly increased (p < 0.01) in the
pVAX-EF-1α group 2 weeks after the last vaccination
(32.43 ± 3.23), compared with that in the pVAXI
(18.84 ± 1.83), PBS (17.93 ± 2.31) and the blank (18.17 ±
1.54) groups. Meanwhile, pVAX-EF-1α group showed the
highest percentage of CD8+ T cells after the last
immunization (14.36 ± 1.76), which was significantly dif-
ferent at (p < 0.01) when compared with the percentages
in the control groups: pVAXI (8.27 ± 1.96), PBS (8.01 ±
1.54) and blank (8.11 ± 1.12) (Table 1 and Fig. 6b).
After the last immunization, the immunized group had a
significantly higher percentage of MHC-I+ cells (32.96 ±
3.04), in contrast to pVAXI (18.14 ± 2.30), PBS (17.76 ±
1.16), and blank (17.88 ± 1.78) groups (Fig. 6c). The amount
of MHC-II+ cells increased over time in the vaccinated
group (Fig. 6d), starting at week 2 of the experiment and
reaching a peak point (8.26 ± 1.23) at week 6 of the experi-
ment that was significantly higher (p < 0.01) than the levels
of MHC-II+ cells in the control groups: pVAXI (3.24 ± 0.53),
PBS (3.11 ± 0.73), and blank (3.22 ± 0.56) (Table 2).
Assessment of the protective efficacy of DNA
immunization of mice against acute T. gondii infection
To analyze the protective efficacy of DNA vaccination
against T. gondii, we assessed the survival time of mice
after infection with 104 tachyzoites of the virulent RH
Fig. 4 The dynamics of humoral response in BALB/c mice induced by DNA vaccination. a. Determination of IgG antibodies in the sera of BALB/c
mice immunized with pVAX-EF-1α, pVAXI, PBS and Blank controls on weeks 0, 2, 4, 6. Determination of IgG subclass (b) IgG1 and (c) IgG2a, (d) levels of
class IgA, (e) levels of class IgM and (f) levels of class IgE in the sera of the immunized BALB/c mice two weeks after the last immunization. Results are
expressed as mean of the OD450 ± SD. (n = 5) and statistically significant difference (P < 0.05) and (P < 0.01) are indicated by (*) and (**), respectively
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strain. The mice immunized with pVAX-EF-1α had a
significantly prolonged survival time (14.1 ± 1.7 days,
p < 0.05) compared with the control mice that re-
ceived either pVAX I or PBS. All of the mice in the
control groups died within 8 days (Fig. 7).
Discussion
In the present study, a DNA vaccine encoding TgEF-1α
was constructed and its capacity to induce highly
significant immune responses and subsequent protection
of BALB/c mice against a lethal dose challenge of the
highly virulent T. gondii RH strain was demonstrated.
Humoral immunity in the form of antigen specific IgG
antibodies seems to be important in controlling T. gondii
invasion [28]. These specific antibodies can inhibit para-
site attachment to the host cell receptors and can pro-
mote macrophages to kill intracellular parasites, which
seem to be important in controlling T. gondii infection
and its reactivation [29]. Here, the high level of anti-T.
gondii IgG antibody was induced in the experimental
group (pVAX-EF-1α vaccinated mice) compared with
the levels in the three control groups (p < 0.05). Further
analyses of the IgG subclasses (IgG1 and IgG2a) revealed
a predominance of IgG2a over IgG1, indicating that
pVAX-EF-1α could elicit a Th1-biased humoral immune
response, which is considered to play a critical role in
the protective immunity against T. gondii [30, 31]. This
result is consistent with those described in previous
studies [31–33].
Immunoglobulins IgA, IgM, and IgE have also been re-
ported to participate in the immunological responses
against T. gondii infection [34–37]. However, less atten-
tion has been paid to these immunoglobulins during
vaccination trials, where the focus has been almost en-
tirely directed to IgG [25, 38, 39]. IgA is important in






Groups (n = 5)
Blank PBS pVAXI pVAX-EF-1a
CD4+ Week 0 18.01 ± 2.95 18.53 ± 2.76 18.23 ± 2.85 17.98 ± 2.45
Week 2 18.41 ± 1.85 18.55 ± 1.96 17.90 ± 2.53 28.18 ± 3.05a
Week 4 18.03 ± 2.84 18.80 ± 2.88 18.15 ± 1.93 30.46 ± 3.59a
Week 6 18.17 ± 1.54 17.93 ± 2.31 18.84 ± 1.83 32.43 ± 3.23a
CD8+ Week 0 8.20 ± 1.55 8.13 ± 1.28 8.47 ± 1.81 8.32 ± 1.65
Week 2 8.32 ± 1.94 8.00 ± 1.48 7.94 ± 1.15 13.23 ± 2.41a
Week 4 8.37 ± 2.07 8.13 ± 1.58 8.25 ± 1.52 12.50 ± 3.11a
Week 6 8.11 ± 1.12 8.01 ± 1.54 8.27 ± 1.96 14.36 ± 1.76a
Data are presented as the mean ± SD (n = 5). a represents statistically highly
significant difference (p < 0.01) as compared with control groups: Blank, PBS
and pVAXI
Fig. 5 Cytokine production. Antibody-captured ELISA was used to determine the production levels of (a) IFN-γ, (b) IL-4, (c) IL-17 and (d) TGF-β1, in sera
samples (n = 5) collected at weeks 0, 2, 4 and 6, and the comparison results were expressed as means ± SD of pg/ml. The asterisk designates statistically
significant differences (* represents p < 0.05; ** represents p < 0.01) between groups. Results presented here were from three independent experiments
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mucosal immunity to oral infection with toxoplasma
cysts [40]. Since antibodies of this isotype are important
in preventing re-infection with T. gondii, inducing IgA
may be a major strategic aspect of vaccine development
[35]. IgM has been reported to increase the phagocytic
capacity of neutrophils and to be potentially capable of
activating the complement cascade, which may result in
killing of the parasite [41, 42]. Moreover, it could reduce
the spread of the parasite by blocking cell invasion [43].
In our study, high titers of IgA and IgM were detected
in the immunized group, indicating that TgEF-1α had
successfully induced the release of these antibodies as
part of the response generated after immunization.
The induction of IgE has been previously recognized
during the T. gondii infection [37, 44]. However, our data
revealed no significant traces of this immunoglobulin
Fig. 6 Flow cytometry strategy. Detection of T lymphocyte subpopulation and MHC molecules using flow cytometry technique (CD3 gated),
a CD4+ T lymphocytes (CD3+CD4+, region Q2). b CD8+ T lymphocytes (CD3+CD8+, region Q2). c MHC-I molecules (CD3+MHC-I, region Q2).
d. MHC-II molecules (CD3+MHC-II, region Q2)
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after vaccination with TgEF-1α, an observation consist-
ent with findings from previous studies [25, 45, 46].
Cytokines play an important role in the activities of T
helper (Th) cells. It is well known that IFN-γ is the cen-
tral cytokine that is responsible for resistance against T.
gondii during both the early and late stages of infection
[47–50]. Compared with the three control treatments,
immunization with pVAX-EF-1α enhanced the Th1 me-
diated immunity by inducing a high level of IFN-γ. In
addition, as a factor of Th2 type immune response, a
slight increase of cytokine IL-4 was also observed. These
results therefore demonstrated that pVAX-EF-1α could
elicit strong Th1 cellular immune responses, which is es-
sential for cell-mediated immunity and resistance against
intracellular pathogens [51, 52]. Similarly, several other
studies reported a distinct pattern of Th1 response to
DNA-based vaccines against T. gondii [30, 45, 53].
IL-17 is produced by Th17 cells and functions as a tissue
inflammatory modulator [54]. This cytokine is also
involved in the resistance against T. gondii infection [55,
56]. In this investigation, a significant increase of IL-17
concentration was detected in pVAX-EF-1α vaccinated
mice over the levels in the control group mice. This finding
indicated that TgEF-1a was capable of inducing Th17 dif-
ferentiation and resulted in an inflammatory reaction.
Additional research regarding this T helper type of
cells is required to further clarify the roles played by
this cell type and the cytokines it releases during vac-
cination against T. gondii.
The cytokine TGF-β produced by regulatory T cells
(Treg cells) plays an integral role in regulating immune re-
sponses. TGF-β has pleiotropic effects on adaptive im-
munity, especially in the regulation of effector and
regulatory CD4+ T cell responses [57]. TGF-β signaling
was activated in astrocytes during toxoplasmic encephal-
itis and inhibition of astrocytic TGF-β signaling increases
immune cell infiltration, uncouples proinflammatory cyto-
kine and chemokine production from the central nervous
system parasite burden, and increases neuronal injury
[58]. Our results showed that no significant production of
TGF-β1 was detected in pVAX-EF-1α vaccinated group.
This finding could be due to its antagonistic relationship
with other cytokines, such as IFN-γ [59–61].
Among the subclasses of T lymphocytes, CD4+ and CD8
+ T lymphocytes play an important role in host resistance
to T. gondii infection [62]. CD3+ CD4+ CD8− is the surface
marker of T helper (Th) cells that can participate in the
adaptive immune responses, while CD3+ CD8+ CD4− is
expressed on cytotoxic T cells (CTLs) which is classified as
a pre-defined cytotoxic role player within the immune sys-
tem [63]. In the present study, we observed differences in
the relative proportions of CD4+ and CD8+ T cells between
the vaccinated and control groups. Specifically, we found
an increase in both of these components in immunized
mice. This observation suggests that immunization with






Groups (n = 5)
Blank PBS PVAXI PVAX-EF-1a
MHC-I Week 0 18.19 ± 2.46 17.17 ± 2.62 16.99 ± 1.38 17.29 ± 2.34
Week 2 16.55 ± 2.15 17.13 ± 1.91 17.06 ± 2.44 24.23 ± 3.33a
Week 4 17.64 ± 1.82 18.02 ± 1.91 17.62 ± 1.46 31.44 ± 3.54a
Week 6 17.88 ± 1.78 17.76 ± 1.16 18.14 ± 2.30 32.96 ± 3.04a
MHC-II Week 0 3.07 ± 0.97 2.88 ± 0.37 3.31 ± 0.49 3.27 ± 0.61
Week 2 2.99 ± 0.71 3.17 ± 0.38 3.07 ± 0.97 4.84 ± 1.86a
Week 4 3.25 ± 0.45 3.17 ± 0.38 3.27 ± 0.59 7.52 ± 1.42a
Week 6 3.22 ± 0.56 3.11 ± 0.73 3.24 ± 0.53 8.26 ± 1.23a
Data are presented as the mean ± SD (n = 5). a represents statistically highly
significant difference (p < 0.01) as compared with control groups: Blank, PBS
and pVAXI
Fig. 7 Survival curve of mice after challenge infection with Toxoplasma gondii RH strain. Mice were challenged with 104 tachyozoites of the RH
strain intraperitoneally two weeks after the third immunization
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pVAX-EF-1α may induce the activation of both CD4+ and
CD8+ T cells, which may contribute synergistically to cyto-
toxic activity against T. gondii infection.
DNA vaccines stimulate both the exogenous (MHC
class II restricted) and the endogenous (MHC class I re-
stricted) antigen presentation pathways [53]. This study
found that both the MHC class I and MHC class II mol-
ecules were up-regulated in the pVAX-EF-1α vaccinated
group compared with their levels in the control groups.
The enhancement of MHC class I expression might be
related to the significant increase of IFN-γ that we
observed in the pVAX-EF-1α vaccinated group. IFN-γ
up-regulates MHC class I expression as well as antigen
processing and presentation on cells via activation of
Janus kinase /Signal transducer and activator of tran-
scription 1 (JAK/STAT1) signal transduction pathway.
Briefly, MHC class I antigen presentation-associated
gene expression is initiated by interferon regulatory
factor-1 (IRF-1). IRF-1 expression is initiated by phos-
phorylated STAT1. IFN-γ binds to IFN receptors, and
then activates JAK1/JAK2/STAT1 signal transduction via
phosphorylation of JAK and STAT1 in cells [64, 65]. An
up-regulation of MHC class I molecules would generally
facilitate the CD8+ cytotoxic T cell killing of T. gondii-
infected cells and may serve to limit parasite multipli-
cation [66]. The up-regulated MHC-II molecules
would be able to present more T. gondii-derived anti-
genic peptides to CD4+ T cells and induce stronger
immune responses during T. gondii infection, leading
to inhibition of the parasite [62].
To evaluate the protection efficacy of the DNA vac-
cine, immunized BALB/c mice were intraperitoneally
challenged with 1 × 104 tachyzoites of the highly virulent
T. gondii RH strain. In this acute infection model, mice
immunized with pVAX-EF-1α had a significantly pro-
longed survival time, demonstrating the protective effi-
cacy of this vaccine, which was similar to the results of
previous studies employing several other single gene
DNA vaccines [25, 45, 67]. but it is not as good as that
of other pVAX vaccination candidates such as pVAX-
eIF4A [68], pVAX-ROP9 [33] and pVAX-ROP8 [69].
Conclusion
In summary, this study revealed that the DNA vaccine
pVAX-EF-1α encoding TgEF-1α can trigger strong
humoral and cellular immune responses, and can induce
a prolonged survival time against lethal T. gondii chal-
lenge. Although TgEF-1α elicited only partial protection
against acute toxoplasmosis, it could be used as a poten-
tial vaccine candidate in further studies of multi-
component T. gondii vaccines against toxoplasmosis.
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